← Back to Search

Anti-epileptic drug

Seizure Prophylaxis for Seizures

Phase 4
Waitlist Available
Led By Richard Gonzalez, MD
Research Sponsored by Loyola University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who have suffered intracranial injury identified by CT Scan
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial will test whether anti-seizure medication can prevent seizures in brain injury patients and improve outcomes.

Eligible Conditions
  • Seizures
  • Traumatic Brain Injury

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Seizures (count of seizures)
Secondary outcome measures
Mortality

Side effects data

From 2006 Phase 4 trial • 251 Patients • NCT00160654
30%
Somnolence
14%
Dizziness
6%
Fatigue
6%
Nausea
6%
Headache
6%
Sedation
2%
Convulsion
1%
Grand mal convulsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Levetiracetam

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Seizure ProphylaxisExperimental Treatment1 Intervention
Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
Group II: No seizure prophylaxisActive Control1 Intervention
Participants randomized to this arm will not receive anti-seizure prophylaxis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Levetiracetam
FDA approved

Find a Location

Who is running the clinical trial?

Loyola UniversityLead Sponsor
156 Previous Clinical Trials
29,122 Total Patients Enrolled
Richard Gonzalez, MDPrincipal InvestigatorLoyola University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~300 spots leftby Mar 2025